The overarching objective of Immune-Image is to develop a novel non-invasive imaging strategy for assessing immune cell activation and dynamics in oncology and inflammatory disease, in animal models and in patients. To achieve this goal, 22 organisations will be working in 7 workpackages during 5 years.
Specifically, within Immune-Image we will:
Develop an infrastructure for data sharing, harmonisation and biobanking.
Generate imaging agents for characterisation of specific immune cell subsets.
Develop and optimise imaging workflows and conduct proof-of-principle studies.
Validate immunotracers in disease models with the aim of making them applicable to clinical studies.
Conduct human clinical trials to confirm safety and to evaluate the clinical potential of novel immunotracers.
WORKPACKAGES
WP1. Management, coordination, dissemination and sustainability
WP1 leaders:
Bert Windhorst (VUMC)
Jason Hannon (Roche)
Partners involved: VUMC, WWU, TTOP, Lawrencium, ECPC, Roche
WP2. Data storage and analysis enablement
WP2 Leaders:
Jan-Willem Boiten (Lygature)
Patricia Cole (Bayer)
Partners involved: VUMC, UMCG, Antaros, LYG, Lawrencium, ECPC, Bayer, Janssen, Takeda
WP3. Generation of imaging reagents to uniquely identify
specific cell types
WP3 Leaders:
Nick Devoogdt (VUB)
Wouter Driessen (Roche)
Partners involved: VUMC, EKUT, WWU, VUB, VIB, UMCG, Roche, Janssen, Pfizer, Takeda
WP4. Immune cell imaging technique development and tracer validation
WP4 Leaders:
Manfred Kneilling/Bernd Pichler (EKUT)
Bastian Zinnhardt (Roche)
Partners involved: VUMC, EKUT, UCAM, WWU, VUB, VIB, UMCG, VHIO, VHIR, Roche, Bayer, Janssen, Pfizer
WP5. Implementation of immunotracers for longitudinal assessment and therapy monitoring in pre-clinical disease models in vivo
WP5 Leaders:
Andreas Jacobs/Michael Schäfers (WWU)
Ian Wilson (ImaginAb)
Partners involved: VUMC, EKUT, UCAM, WWU, VUB, VIB, UMCG, VHIO, VHIR, CEA, Roche, Bayer, Janssen, Pfizer, ImaginAb, Takeda
WP6. Trials with immunotracers in patients with cancer and inflammatory diseases
WP6 Leaders:
Elisabeth de Vries (UMCG)
Nicholas Seneca (Novartis)
Partners involved: VUMC, EKUT, UCAM, WWU, VUB, UMCG, VHIO, VHIR, Antaros, LYG, Roche, Bayer, Janssen, Novartis, Pfizer, ImaginAb, Takeda
WP7. Ethics requirements
Partners involved: VUMC
General information
Project acronym: Immune-Image
Full project title: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies
Grant Agreement ID: 831514
Project start date: 1 October 2019
Project end date: 31 March 2026
Project duration: 77 months
Project budget: € 27,200,801.38
EU contribution: € 15,000,000
EFPIA contribution: € 12,200,801.38
Project leads: Bert Windhorst (VUMC) and Jason Hannon (Roche)
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831514. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
